# What did CJC-1295 change in blood? > CJC-1295 | Growth Hormone Axis research peptides — Growth Hormone Axis research peptides: CJC-1295 raised blood hormones for days in small adult tests. Lasting health benefits and safety remain uncertain. **03 / Raised hormones, unproved health gains** Hormone levels stayed raised for days in small adult studies. Those blood tests didn't show that you would gain strength or recover sooner. ## What the small adult studies left unproved Researchers tested the drug among few adults, all healthy. Hormones rose with CJC-1295; your lasting health benefit remains unproved. Growth hormone and a growth-helping protein from the liver rose [15][16]. The gland continued its usual bursts of growth hormone release. Blood tests didn't measure improved health over many years. Sleep, muscle gain and slower aging remained unproved. CJC-1295 imitates the brain's hormone message to the growth-hormone gland. Changed parts help keep the drug from breaking down quickly. DAC is the added attachment on the form that acts longer. The attachment joins the drug to a blood protein called albumin. Held by albumin, the drug stays active longer in blood. Without the attachment, CJC-1295 no-DAC has a shorter action. These study results don't give the drug approval to treat people. A hormone rise isn't permission to treat a medical problem. Ask whether the study you're discussing used the attached form. Longer action leaves lasting benefits and harms needing further tests. ## What attachment to a blood protein changes Four parts were changed in CJC-1295 to slow its breakdown. The gland releases growth hormone in response to this drug. An added part, DAC, attaches the drug to albumin. The drug's action lasts longer when this blood protein carries it. CJC-1295 with DAC means the form with that attachment. CJC-1295 no-DAC lacks the attachment, so the drug acts less long. The unattached form copies a portion of the brain's hormone message. Its shorter action matters when discussing what a study found. Advertisements sometimes describe both forms as though they were identical. For your safety question, the attachment changes how long the drug acts. Investigators tested material of unknown contents during sports-drug checks [13]. They found the longer-lasting form in that particular material. Other bottles remained untested for their contents. Naming the drug on your bottle doesn't establish what's inside. Keep the form's name beside the finding you're considering. The shorter form wasn't proved to share the longer form's results. ## What changed between the gland’s usual hormone bursts A small study in men mostly measured hormone release [16]. The researchers didn't follow health improvements over years of treatment. The gland normally releases little growth hormone between larger bursts. Treatment raised that lower level, while the usual bursts continued. Average growth hormone also rose, together with the liver's growth-helping protein. The bursts themselves didn't become larger or more frequent. The gland stores growth hormone; CJC-1295 prompts release of that store. The brain usually sends the message to release that hormone. The liver's growth-helping protein rises when growth hormone prompts its release. Slow breakdown and attachment in blood keep the drug's prompting going. A review described changes that make these drugs act longer [8]. Longer action wasn't shown to be safer for you. Continuous prompting doesn't mean the gland releases hormone without a pause. The gland's bursts continued despite the drug remaining active. Your question may concern gaining strength or recovering after exercise. Neither benefit was proved by watching the blood hormones rise. ## What days of raised blood readings did and did not show The few adults studied were healthy, without the illnesses treatment might target. Researchers measured hormones and other blood proteins, without proving daily health gains. One treatment kept growth hormone raised six days or longer. The liver protein's raised level lasted nine to eleven days [15]. Giving larger amounts of the drug produced higher hormone readings. Repeated treatment kept the liver protein raised up to twenty-eight days. The amount of drug in blood fell slowly. Those results concern the longer-lasting form with the DAC attachment. Another small study checked healthy young men after one week [16]. Growth hormone averaged roughly forty-five percent higher; the liver protein rose similarly. The average combines the low readings with the high readings during bursts. Growth hormone also rose from its usual low level between bursts. The low level between bursts and the overall average are different measurements. The bursts didn't grow larger or arrive more often. A separate study checked blood proteins in eleven healthy men [14]. After treatment, several proteins changed; some rose and others fell. Other blood proteins changed along with the liver's growth-helping protein. The tests didn't show whether these protein changes benefited the men. Investigators separately found CJC-1295 in seized material of unknown contents [13]. The discovery didn't show that treatment with the drug was safe. Researchers could detect these hormone changes after the drug acted. Better sleep or exercise recovery still needs direct study in people. ## What users noticed, and what safety tests leave open **Users trying CJC-1295 for research give these accounts, outside controlled trials. Comparing treatment with placebo hasn't checked their accounts, which remain personal reports.** Some describe deeper sleep, easier recovery and a leaner appearance. They also mention body fat decreasing gradually during use. Swollen hands and puffiness appear among reported problems. Keeping extra water in the body may account for the swelling. Other accounts mention headaches, warm red skin and irritation after shots. Hand tingling, fatigue, appetite changes and higher blood sugar appear too. People may use other drugs while bottle contents remain uncertain. The reports can't show which drug caused changes or how often problems happen. The papers describe CJC-1295 as unapproved for treating people. They don't check the current approval rules where you live. In small human tests, growth hormone rose alongside the liver's growth-helping protein [15][16]. The tests were too brief to settle years of possible harm. Questions include swelling, blood sugar and faster growth of existing tumors. The hormone-action review doesn't supply years of safety testing [8]. Finding the drug in seized material didn't test other bottles [13]. Confusing the attached and unattached forms also hides a difference in timing. Your question about years of use needs longer human studies. Personal accounts can't establish lasting safety or a treatment benefit. ## What longer prompting has yet to prove Most CJC-1295 tests followed the time hormones stayed raised. Those results didn't establish a useful treatment for patients. [Tesamorelin](/tesamorelin) and [sermorelin](/sermorelin) also prompt the growth-hormone gland to release hormone. CJC-1295 keeps prompting the gland while the usual hormone bursts continue. Tesamorelin has fat-loss trials supporting its particular approved treatment. CJC-1295 can't gain that proof from another drug's patients. [Ipamorelin](/ipamorelin) works more like the hormone that controls hunger. These papers don't prove benefits from using the drugs together. For your health, the improvement you want needs direct measurement. Raised hormones lasting for days don't measure sleep or recovery. The [comparison](/compare) puts the people tested beside the measured changes. Check that match when discussing your proposed treatment. ![CJC-1295 illustration showing its lasting hormone effect](/images/cjc-1295.webp) --- An independent reading of the GH-axis literature—study populations and endpoints, never a treatment plan.